H.C. Wainwright raised the firm’s price target on Corcept Therapeutics to $38 from $28 and keeps a Buy rating on the shares post the Q4 report. The analyst says strong Korlym growth is anticipated for 2024 and that the landmark CATALYST study could help expand the market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT:
- Corcept Therapeutics Reports Latest Quarterly Results and Update
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
- CORT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
